Who
Simon H. Stertzer
Director
Company insider
Files Form 4 as: Director and 10% owner, BioCardia.
In numbers
- Trades disclosed
- 72
- Buys
- 30
- Sells
- 0
- Bought
- $10.4M
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 1 Nov 2016
- Last trade
- 6 Jul 2026
- Last filed
- 7 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Jul 2026filed 7 Jul 2026 | BCDA BioCardiaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 6 Jul 2026filed 7 Jul 2026 | BCDA BioCardiaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 23 Jun 2026filed 24 Jun 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $39K39,000 at $1.00 | filing |
| 23 Jun 2026filed 24 Jun 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $39K39,000 at $1.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $65K70,200 at $0.92 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $65K70,200 at $0.92 | filing |
| 8 Dec 2025filed 10 Dec 2025 | BCDA BioCardiaoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 19 Sep 2025filed 23 Sep 2025 | BCDA BioCardiaoption or derivative · Biotechnology | SEC FORM 4 Code P | —398,400 | filing |
| 19 Sep 2025filed 23 Sep 2025 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $498K398,400 at $1.25 | filing |
| 30 Jun 2025filed 2 Jul 2025 | BCDA BioCardiaoption or derivative · Biotechnology | SEC FORM 4 Code P | —72,289 | filing |
| 30 Jun 2025filed 2 Jul 2025 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $150K72,289 at $2.08 | filing |
| 23 Apr 2025filed 25 Apr 2025 | BCDA BioCardiaoption or derivative · Biotechnology | SEC FORM 4 Code P | —104,986 | filing |
| 23 Apr 2025filed 25 Apr 2025 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $201K104,986 at $1.91 | filing |
| 5 Mar 2025filed 7 Mar 2025 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $2,4501,000 at $2.45 | filing |
| 4 Mar 2025filed 5 Mar 2025 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $36K15,536 at $2.30 | filing |
| 3 Mar 2025filed 5 Mar 2025 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $52K22,753 at $2.30 | filing |
| 11 Oct 2024filed 16 Oct 2024 | BCDA BioCardiaoption or derivative · Biotechnology | SEC FORM 4 Code A | —829 at $0.00 | filing |
| 18 Oct 2023filed 19 Oct 2023 | BCDA BioCardiaoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,434 at $0.00 | filing |
| 23 Jun 2023filed 26 Jun 2023 | BCDA BioCardiaBiotechnology | SEC FORM 4 Code A | $150K64,212 at $2.34 | filing |
| 16 Dec 2022filed 19 Dec 2022 | BCDA BioCardiaBiotechnology | SEC FORM 4 Code A | $300K178,571 at $1.68 | filing |
News
BioCardia (NASDAQ:BCDA) Stock Falls 5.5% – What's Next?BCDA · dailypolitical.com · 23 Oct 2026BioCardia Advances Helix Catheter Toward FDA Marketing ClearanceBCDA · rttnews.com · 19 Oct 2026BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this QuarterBCDA · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Simon H. Stertzer; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.